House Bills Would Close Orphan Exclusivity ‘Loophole’ And Thaw ‘Frozen’ Generic Labeling
Executive Summary
US FDA-related legislation among the bills moving during the lame duck session of Congress.
You may also be interested in...
BsUFA III: Reauthorization Process Begins With US FDA Considering Staffing, Uptake Issues
Biosimilar availability may not be in the its purview, but the FDA still is thinking about ways to help industry deal with the issue and support sector growth.
Orphan Exclusivity: Rarely Used, But Well-Known, Loophole Would Be Closed By House Legislation
US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.
Continuous Manufacturing: Cost, Lack Of Know-How Have Deterred Generic Firms, Prof Says
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: